Skip Nav Destination
Issues
15 July 2021
-
Cover Image
Cover Image
The image shows a pulmonary invasive mucinous adenocarcinoma (IMA)—a clinicopathologically and molecularly highly distinct subtype of lung adenocarcinoma. The tumor in the image harbors an NRG1 fusion; this type of IMA was found to exhibit more aggressive histologic and clinical features compared with IMA with KRAS mutations. Among KRAS wild-type IMA, NRG1 and other fusions were identified in over half of the cases, leading to durable responses to targeted therapies in some patients, which highlights the importance of fusion testing in this tumor type. For details, see the article by Chang and colleagues on page 4066 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Clinical Trials: Targeted Therapy
Author Choice
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors
Naoko Takebe; Abdul Rafeh Naqash; Geraldine O'Sullivan Coyne; Shivaani Kummar; Khanh Do; Ashley Bruns; Lamin Juwara; Jennifer Zlott; Larry Rubinstein; Richard Piekarz; Elad Sharon; Howard Streicher; Arjun Mittra; Sarah B. Miller; Jiuping Ji; Deborah Wilsker; Robert J. Kinders; Ralph E. Parchment; Li Chen; Ting-Chia Chang; Biswajit Das; Ganesh Mugundu; James H. Doroshow; Alice P. Chen
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Elio Adib; Katarzyna Klonowska; Krinio Giannikou; Khanh T. Do; Solida Pruitt-Thompson; Ketki Bhushan; Matthew I. Milstein; Jennifer Hedglin; Katherine E. Kargus; Lynette M. Sholl; Junko Tsuji; David M. Hyman; Anne Sisk; Geoffrey I. Shapiro; Hebert A. Vargas; James J. Harding; Martin H. Voss; Gopa Iyer; David J. Kwiatkowski
Author Choice
Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma
Brian A. Van Tine; Angela C. Hirbe; Peter Oppelt; Ashley E. Frith; Richa Rathore; Joshua D. Mitchell; Fei Wan; Shellie Berry; Michele Landeau; George A. Heberton; John Gorcsan, III; Peter R. Huntjens; Yoku Soyama; Justin M. Vader; Jose A. Alvarez-Cardona; Kathleen W. Zhang; Daniel J. Lenihan; Ronald J. Krone
Author Choice
Prospective Evaluation of Doxorubicin Cardiotoxicity in Patients with Advanced Soft-tissue Sarcoma Treated in the ANNOUNCE Phase III Randomized Trial
Robin L. Jones; Andrew J. Wagner; Akira Kawai; Kazuo Tamura; Ashwin Shahir; Brian A. Van Tine; Javier Martín-Broto; Patrick M. Peterson; Jennifer Wright; William D. Tap
A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Komal Jhaveri; Joshua Z. Drago; Payal Deepak Shah; Rui Wang; Fresia Pareja; Fanni Ratzon; Alexia Iasonos; Sujata Patil; Neal Rosen; Monica N. Fornier; Nancy T. Sklarin; Sarat Chandarlapaty; Shanu Modi
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAFV600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism
Baptiste Louveau; Matthieu Resche-Rigon; Thierry Lesimple; Laetitia Da Meda; Marc Pracht; Barouyr Baroudjian; Julie Delyon; Mona Amini-Adle; Caroline Dutriaux; Coralie Reger de Moura; Aurélie Sadoux; Fanélie Jouenne; Zineb Ghrieb; Paul Vilquin; Didier Bouton; Annick Tibi; Samuel Huguet; Keyvan Rezai; Maxime Battistella; Samia Mourah; Céleste Lebbe
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
Lauren Averett Byers; Dmitry Bentsion; Steven Gans; Konstantin Penkov; ChoonHee Son; Anne Sibille; Taofeek K. Owonikoko; Harry J.M. Groen; Carl M. Gay; Junya Fujimoto; Patricia de Groot; Martin Dunbar; Kingston Kang; Lei He; Vasudha Sehgal; Jaimee Glasgow; Bruce Allen Bach; Peter M. Ellis
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer
Priyanka Sharma; Vandana G. Abramson; Anne O'Dea; Lauren Nye; Ingrid Mayer; Harsh B. Pathak; Marc Hoffmann; Shane R. Stecklein; Manana Elia; Sharon Lewis; Jecinta Scott; Jilliann A. De Jong; Yen Y. Wang; Rachel Yoder; Kelsey Schwensen; Karissa Finke; Jaimie Heldstab; Stephanie LaFaver; Stephen K. Williamson; Milind A. Phadnis; Gregory A. Reed; Bruce F. Kimler; Qamar J. Khan; Andrew K. Godwin
First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors
Toshio Shimizu; Yutaka Fujiwara; Kan Yonemori; Takafumi Koyama; Jun Sato; Kenji Tamura; Akihiko Shimomura; Hiroki Ikezawa; Maiko Nomoto; Keiji Furuuchi; Ryo Nakajima; Takuma Miura; Noboru Yamamoto
Clinical Trials: Immunotherapy
Modified RANO, Immunotherapy RANO, and Standard RANO Response to Convection-Enhanced Delivery of IL4R-Targeted Immunotoxin MDNA55 in Recurrent Glioblastoma
Benjamin M. Ellingson; John Sampson; Achal Singh Achrol; Manish K. Aghi; Krystof Bankiewicz; Chencai Wang; Martin Bexon; Steven Brem; Andrew Brenner; Sajeel Chowdhary; John R. Floyd; Seunggu Han; Santosh Kesari; Dina Randazzo; Michael A. Vogelbaum; Frank Vrionis; Miroslaw Zabek; Nicholas Butowski; Melissa Coello; Nina Merchant; Fahar Merchant
Author Choice
Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer
Ming Lei; Nathan O. Siemers; Dimple Pandya; Han Chang; Teresa Sanchez; Christopher Harbison; Peter M. Szabo; Yelena Janjigian; Patrick A. Ott; Padmanee Sharma; Johanna Bendell; Thomas R. Jeffry Evans; Filippo de Braud; Ian Chau; Zachary Boyd
Precision Medicine and Imaging
A Novel Topical Fluorescent Probe for Detection of Glioblastoma
Yosuke Kitagawa; Shota Tanaka; Mako Kamiya; Yugo Kuriki; Kyoko Yamamoto; Takenori Shimizu; Takahide Nejo; Taijun Hana; Reiko Matsuura; Tsukasa Koike; Erika Yamazawa; Yoshihiro Kushihara; Satoshi Takahashi; Masashi Nomura; Hirokazu Takami; Shunsaku Takayanagi; Akitake Mukasa; Yasuteru Urano; Nobuhito Saito
Deep Learning for Fully Automated Prediction of Overall Survival in Patients with Oropharyngeal Cancer Using FDG-PET Imaging
Nai-Ming Cheng; Jiawen Yao; Jinzheng Cai; Xianghua Ye; Shilin Zhao; Kui Zhao; Wenlan Zhou; Isabella Nogues; Yuankai Huo; Chun-Ta Liao; Hung-Ming Wang; Chien-Yu Lin; Li-Yu Lee; Jing Xiao; Le Lu; Ling Zhang; Tzu-Chen Yen
Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Mikiko Suzuki; Shigehiro Yagishita; Kiyoshi Sugihara; Yusuke Ogitani; Tadaaki Nishikawa; Mayu Ohuchi; Takashi Teishikata; Takahiro Jikoh; Yasushi Yatabe; Kan Yonemori; Kenji Tamura; Kosei Hasegawa; Akinobu Hamada
Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
Rachel Bleach; Stephen F. Madden; James Hawley; Sara Charmsaz; Cigdem Selli; Katherine M. Sheehan; Leonie S. Young; Andrew H. Sims; Pavel Souček; Arnold D. Hill; Marie McIlroy
Translational Cancer Mechanisms and Therapy
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Catherine C. Smith; Aaron D. Viny; Evan Massi; Cyriac Kandoth; Nicholas D. Socci; Franck Rapaport; Matthieu Najm; Juan S. Medina-Martinez; Elli Papaemmanuil; Theodore C. Tarver; Henry H. Hsu; Mai H. Le; Brian West; Gideon Bollag; Barry S. Taylor; Ross L. Levine; Neil P. Shah
Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer
Aslamuzzaman Kazi; Liwei Chen; Shengyan Xiang; Rajanikanth Vangipurapu; Hua Yang; Francisca Beato; Bin Fang; Terence M. Williams; Kazim Husain; Patrick Underwood; Jason B. Fleming; Mokenge Malafa; Eric A. Welsh; John Koomen; José Trevino; Saïd M. Sebti
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Elio Adib; Amin H. Nassar; Elie W. Akl; Sarah Abou Alaiwi; Pier Vitale Nuzzo; Tarek H. Mouhieddine; Guru Sonpavde; Robert I. Haddad; Kent W. Mouw; Marios Giannakis; F. Stephen Hodi; Sachet A. Shukla; Alexander Gusev; David A. Braun; Toni K. Choueiri; David J. Kwiatkowski
Fibroblast Activation Protein α-Targeted CD40 Agonism Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Antitumor Immunity
Eva Sum; Moritz Rapp; Philipp Fröbel; Marine Le Clech; Harald Dürr; Anna Maria Giusti; Mario Perro; Dario Speziale; Leo Kunz; Elena Menietti; Peter Brünker; Ulrike Hopfer; Martin Lechmann; Andrzej Sobieniecki; Birte Appelt; Roberto Adelfio; Valeria Nicolini; Anne Freimoser-Grundschober; Whitney Jordaan; Sara Labiano; Felix Weber; Thomas Emrich; François Christen; Birgit Essig; Pedro Romero; Christine Trumpfheller; Pablo Umaña
CD40 Agonist Targeted to Fibroblast Activation Protein α Synergizes with Radiotherapy in Murine HPV-Positive Head and Neck Tumors
Sara Labiano; Vincent Roh; Céline Godfroid; Agnès Hiou-Feige; Jackeline Romero; Eva Sum; Moritz Rapp; Gael Boivin; Tania Wyss; Christian Simon; Jean Bourhis; Pablo Umaña; Christine Trumpfheller; Genrich V. Tolstonog; Marie-Catherine Vozenin; Pedro Romero
Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes
Jason C. Chang; Michael Offin; Christina Falcon; David Brown; Brian R. Houck-Loomis; Fanli Meng; Vasilisa A. Rudneva; Helen H. Won; Sharon Amir; Joseph Montecalvo; Patrice Desmeules; Kyuichi Kadota; Prasad S. Adusumilli; Valerie W. Rusch; Sarah Teed; Joshua K. Sabari; Ryma Benayed; Khedoudja Nafa; Laetitia Borsu; Bob T. Li; Alison M. Schram; Maria E. Arcila; William D. Travis; Marc Ladanyi; Alexander Drilon; Natasha Rekhtman
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Landon C. Brown; Susan Halabi; Joseph D. Schonhoft; Qian Yang; Jun Luo; David M. Nanus; Paraskevi Giannakakou; Russell Z. Szmulewitz; Daniel C. Danila; Ethan S. Barnett; Emily A. Carbone; Jimmy L. Zhao; Patrick Healy; Monika Anand; Audrey Gill; Adam Jendrisak; William R. Berry; Santosh Gupta; Simon G. Gregory; Richard Wenstrup; Emmanuel S. Antonarakis; Daniel J. George; Howard I. Scher; Andrew J. Armstrong
Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Céline M. Laumont; Maartje C.A. Wouters; Julian Smazynski; Nicole S. Gierc; Elizabeth A. Chavez; Lauren C. Chong; Shelby Thornton; Katy Milne; John R. Webb; Christian Steidl; Brad H. Nelson
Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection
Joshua S. Jolissaint; Kevin C. Soares; Kenneth P. Seier; Ritika Kundra; Mithat Gönen; Paul J. Shin; Thomas Boerner; Carlie Sigel; Ramyasree Madupuri; Efsevia Vakiani; Andrea Cercek; James J. Harding; Nancy E. Kemeny; Louise C. Connell; Vinod P. Balachandran; Michael I. D'Angelica; Jeffrey A. Drebin; T. Peter Kingham; Alice C. Wei; William R. Jarnagin
Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases
Inna Smalley; Zhihua Chen; Manali Phadke; Jiannong Li; Xiaoqing Yu; Clayton Wyatt; Brittany Evernden; Jane L. Messina; Amod Sarnaik; Vernon K. Sondak; Chaomei Zhang; Vincent Law; Nam Tran; Arnold Etame; Robert J.B. Macaulay; Zeynep Eroglu; Peter A. Forsyth; Paulo C. Rodriguez; Y. Ann Chen; Keiran S.M. Smalley
Letters to the Editor
Corrections
Correction: Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR–mediated DNA Damage Response
Li Ding; Vijay S. Madamsetty; Spencer Kiers; Olga Alekhina; Andrey Ugolkov; John Dube; Yu Zhang; Jin-San Zhang; Enfeng Wang; Shamit K. Dutta; Daniel M. Schmitt; Francis J. Giles; Alan P. Kozikowski; Andrew P. Mazar; Debabrata Mukhopadhyay; Daniel D. Billadeau
Correction: Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients
Toni M. Brand; Stefan Hartmann; Neil E. Bhola; Noah D. Peyser; Hua Li; Yan Zeng; Erin Isaacson Wechsler; Max V. Ranall; Sourav Bandyopadhyay; Umamaheswar Duvvuri; Theresa M. LaVallee; Richard C.K. Jordan; Daniel E. Johnson; Jennifer R. Grandis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.